Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Figitumumab + Chemo in ES-SCLC
NCT00977561Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Apr 2010
- Primary completion
- Oct 2011
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of figitumumab in small cell lung cancer (SCLC), sponsored by Pfizer. Started Apr 2010; status: terminated.
02
Drugs
figitumumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00977561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00977561.